ArticleThe western journal of emergency medicine2026
Rapid Turnaround Time for Toxic Alcohol Testing Is Associated with Shorter Hospital Length of Stay.
Article in The western journal of emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionToxic alcohol poisoning (methanol or ethylene glycol) can cause severe metabolic disturbances, end-organ damage, and death. Timely diagnosis is paramount and predicated on history, lab markers, and confirmatory laboratory testing, which inform antidote use and/or hemodialysis. Confirmatory toxic alcohol testing capabilities and turnaround times vary by geographic region. Our objective in this study was to evaluate how differences in toxic alcohol testing turnaround times impact our primary outcome of hospital length of stay and secondary outcomes of antidote (fomepizole) administration and medical outcomes (including death, major, moderate, and minor effects) among patients with suspected toxic alcohol poisoning.
methodsThis is a retrospective cohort study of toxic alcohol poisoning cases reported to two U.S. poison centers, Michigan Poison and Drug Information Center (MiPDC) and Florida's Poison Information Network (FPIN), from 2018-2022. Based on investigator experience with each center's practice patterns, MiPDC had a toxic alcohol testing turnaround time of 12-24 hours, while FPIN had turnaround times averaging 5-7 days. We queried poison center databases for cases where fomepizole was recommended and/or administered. Medical outcomes were categorized using National Poison Database System definitions: minor effects (minimally bothersome symptoms); moderate effects (pronounced symptoms requiring treatment); major effects (life-threatening or significant disability); and death. We excluded cases if there was no concern for toxic alcohol poisoning or if fomepizole was administered for acetaminophen poisoning.
resultsA total of 963 cases met inclusion criteria: (MiPDC, n = 590; and FPIN, n = 373). Patients reported to FPIN had a longer median hospital length of stay compared to MiPDC (65.0 versus 48.0 hours, P < .001). FPIN patients received more doses of fomepizole (2.0 versus 1.0 doses, P < .001). FPIN patients had 4.1 times the odds of major effect (95% CI, 1.3-13.3) (P = .02) and 4.7 times the odds of minor effect (95% CI, 1.4-15.8) (P = .01), without significant association for moderate effects or death.
conclusionAccess to rapid confirmatory toxic alcohol testing was associated with shorter hospital length of stay, reduced antidote use, and improved medical outcomes in suspected toxic alcohol poisonings. Future studies are warranted to comprehensively characterize the variation in region-specific care and inform efforts to standardize confirmatory testing capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.